Robert W. Baird upgraded shares of LivaNova (NASDAQ:LIVN – Free Report) from a neutral rating to an outperform rating in a research note released on Tuesday morning, MarketBeat.com reports. The brokerage currently has $66.00 target price on the stock, up from their previous target price of $55.00.
Other research analysts also recently issued reports about the company. Stifel Nicolaus boosted their price objective on LivaNova from $70.00 to $72.00 and gave the company a buy rating in a research note on Thursday, July 25th. Needham & Company LLC boosted their price objective on LivaNova from $72.00 to $75.00 and gave the company a buy rating in a research note on Wednesday, July 31st. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $70.80.
Get Our Latest Research Report on LivaNova
LivaNova Price Performance
LivaNova (NASDAQ:LIVN – Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, beating the consensus estimate of $0.66 by $0.15. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. The firm had revenue of $318.60 million during the quarter, compared to analyst estimates of $305.05 million. Equities research analysts anticipate that LivaNova will post 2.58 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in LIVN. BNP Paribas Financial Markets boosted its stake in LivaNova by 98.3% in the 4th quarter. BNP Paribas Financial Markets now owns 22,338 shares of the company’s stock worth $1,156,000 after purchasing an additional 11,075 shares during the period. Dimensional Fund Advisors LP boosted its stake in LivaNova by 6.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,241,985 shares of the company’s stock worth $64,262,000 after purchasing an additional 74,067 shares during the period. Principal Financial Group Inc. boosted its position in shares of LivaNova by 2.4% during the 4th quarter. Principal Financial Group Inc. now owns 225,385 shares of the company’s stock valued at $11,661,000 after acquiring an additional 5,329 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its position in shares of LivaNova by 34.6% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 5,521 shares of the company’s stock valued at $286,000 after acquiring an additional 1,418 shares during the last quarter. Finally, Norges Bank bought a new position in shares of LivaNova during the 4th quarter valued at approximately $26,064,000. 97.64% of the stock is currently owned by institutional investors.
About LivaNova
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Further Reading
- Five stocks we like better than LivaNova
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Dividend Payout Ratio Calculator
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Options Trading – Understanding Strike Price
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.